Outcomes of lynch syndrome endometrial surveillance in the Netherlands Authors: Malcolm Scott, Adam N. Rosenthal Published: 2026 We commend Elkenboon et al. for their study,1 highlighting that endometrial cancer surveillance in Lynch syndrome may enable earlier detection and improved prognosis. However, due to its non-randomized design, conclusions about survival are uncertain. Surveillance did however identify some endometrial hyperplasias, potentially justifying hysterectomy, and thus preventing cancer development. The study lacks data on atypical versus non-atypical hyperplasia, and since a third of general population atypical hyperplasia can coexist with endometrial cancer,2 hysterectomy is usually advised. While non-atypical hyperplasia in Lynch syndrome is poorly understood, only around 5% of non-atypical hyperplasia in the general population progresses to endometrial cancer over 20 years.3 We would suggest that non-atypical hyperplasia in Lynch syndrome is a cause for concern and warrants serious consideration of hysterectomy. Furthermore, attributing high number of hyperplasias to over-diagnosis in a non-randomized study could be misleading. The study does not address surveillance intervals, nor whether endometrial cancer was diagnosed between or during surveillance visits, precluding surveillance performance calculations. Crucially, detailed information about adjuvant therapy in ≥ stage 2 cases is omitted. 13.5% of endometrial cancer on surveillance vs. 21% not on surveillance were ≥ stage 3 and would be expected to require more morbid external beam radiotherapy.4 Given the (non-significant) stage-shift (Fig. 1), it would appear that surveillance may have substantially reduced morbidity in the patients diagnosed with endometrial cancer. Based on our experience, offering hysteroscopy and endometrial biopsy under sedation or general anaesthesia may improve uptake and adherence. However, further research is needed to refine surveillance strategies to improve efficacy and patient experience.Fig. 1Proportion of endometrial cancers of known stage diagnosed at Stage 1B or greater; stage 1B/C would usually require at least vaginal brachytherapy if there was significant lymphovascular space invasion; higher stages would usually require external beam radiotherapy ± chemotherapy (numbers extracted from Supplementary Table 2). Proportion of endometrial cancers of known stage diagnosed at Stage 1B or greater; stage 1B/C would usually require at least vaginal brachytherapy if there was significant lymphovascular space invasion; higher stages would usually require external beam radiotherapy ± chemotherapy (numbers extracted from Supplementary Table 2). Contributors MS: conceptualisation, data curation, formal analysis, investigation, methodology, visualisation. ANS: supervision, writing, review and editing. During the preparation of this work the author(s) used chatGPT 4o mini in order to abridge the first draft to fit the word count. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication. Declaration of interests Malcolm Scott reports PhD research funding from an HCA Healthcare Fellowship. Adam Rosenthal was supported by the NIHR Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust and University College London.